Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:
”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.
This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.
Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.
Patients living with HHT can’t wait for effective therapies to improve their lives.”
Quoting Vaderis Therapeutics AG‘s post:
”Moving Forward Together for the HHT Community
We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).
This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.
While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.
As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.
Read the full press release.”
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 20:46Grace Choung: A Novel CFHR5 Copy Number Variant in Postpartum Atypical HUS
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:40Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia
-
Jul 23, 2026, 19:25William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100